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Introduction: About one third of the world's population is infected with 
tuberculosis (TB) and each year, about 1.5 to 2 million people die from TB. 
Procalcitonin (PCT) is an inflammatory marker that its level has variable results. 
There are some discussions in the utilization of PCT as a diagnostic marker in 
active pulmonary TB. The aim of this study was to compare serum PCT before and 
after treatment in patients with pulmonary TB. 
Materials and Methods: This study was conducted on patients with pulmonary 
TB. Data were collected using a check list. The serum level of PCT was measured 
by ELISA test at the beginning and after six months of treatment. All data were 
analyzed using SPSS 16. 
Results: Forty-two patients with active pulmonary TB entered in this study. The 
mean age of the patients was 45.48±12.54 years and 54.8% of them were male. Most 
of the patients (59.5 %) were rural inhabitants. There was a family history of TB in 
26% of patients. The most common symptom (45.2%) was cough. Mean PCT prior to 
treatment was 1.25±0.98 ng/ml. and 81% of the patients had PCT higher than 0.5 to 
5. After treatment PCT level reduced significantly (P<0.001). The mean erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) before treatment were 
45.88±21.87 and 7.16±3.98 respectively that were reduced significantly after 
treatment (P<0.001). Neutrophil counts before treatment was 6221±3161 Cells per 
ml. and decreased statistically significant after treatment (P=0.01).  
Conclusion: Our results showed that the PCT levels in pulmonary TB were high in 
active disease and reduced after treatment. PCT level may be used for follow-up as 
a discriminative marker between active and cured pulmonary TB and predict 
treatment response, although the PCT assay cannot be substituted for 
microbiological and pathological data. 
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Introduction 
Tuberculosis (TB) is one of the important 
causes of mortalities in developing countries and 
is one of the 8 leading cause of death due to 
diseases in the world. In 2010, about 8.8 million 
people worldwide were infected with TB and 1.4 
million people will annually die from the disease 
(1). The World Health Organization estimates 
 
that approximately one-third of the world's 
population are infected with TB (latent TB) or at 
the disease risk (2).  
Most people diagnosed with TB are living in 
developing countries (3). Despite of medical 
advances, pulmonary TB is still one of the causes 
of death and disability in our communities (4).  
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The diagnosis of TB, as the first step in the 
treatment of patients, has an important and special 
status. Despite the existence of various diagnostic 
methods, detection of mycobacterium tuberculosis 
(in direct smear and staining) is still the only 
reliable method for diagnosis of tuberculosis in 
developing countries. Conventional diagnostic 
methods including sputum smear, culture and 
pathologic study had some limitations (3, 5). 
Therefore, the advanced methods for rapid 
diagnosis of microbe are clear. Biomarkers as 
diagnostic tests to determine the risk of 
developing disease, guidance the treatment, and 
determine the stage of disease progression are 
being used (6). 
Procalcitonin (PCT) is a propeptide calcitonin 
hormone consists of 116 aminoacids with a 
molecular weight of 13 KDa , which is secreted 
from neuroendocrine cells in the thyroid gland 
and from the liver and lung in response to 
endotoxins and tumor necrosis factor-α (TNF-α) 
(7-9). This peptide cannot be detected in the 
serum of healthy subjects and primarily it 
increases in the serum of patients in response to 
infectious disease. The serum level of PCT has a 
correlation with the severity of pulmonary 
infections and also prognosis of patients after 
pulmonary infection (10- 12). 
PCT has been used as a biomarker to 
differentiate viral from bacterial infections, a 
guide for respiratory infections, for evaluating 
the response to treatment of bacterial infections 
in areas where TB incidence is not high (7). 
In a study by Kang and colleagues, serum PCT 
was lower in patients with TB disease compared 
to pulmonary bacterial infection (7). Rasmussen 
and colleagues found that PCT levels in TB 
patients were higher compared with the healthy 
control group. Although its level was lower in 
comparison with patients with pneumonia and he 
concluded that the PCT can be used to predict 
mortality of TB patients (13). In a study 
demonstrated by Ugajin and colleagues in 
patients infected with TB, the serum level of PCT 
was low and the level higher than 0.5 ng/ml was 
associated with poor outcome in patients (14). 
The purpose of this study was to evaluate the 
serum level of PCT in patients with active 
pulmonary TB before treatment and compare 
with the level after successful anti- tuberculosis 
treatment for determining the role of PCT an 
inflammatory marker in active pulmonary TB. 
 
Materials and Methods 
In this semi-experimental study, 42 patients 
with active pulmonary TB, based on positive 
smear of sputum or bronchoalveolar lavage 
(BAL) for Mycobacterium tuberculosis were 
enrolled into this study from September 2011 to 
September 2012 in Internal Medicine department 
of Ardabil University of Medical Sciences. For all 
patients before treatment, a check list included 
demographic information was collected. Then, 
serum samples were obtained to check complete 
blood counts (CBC), erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), and serum 
PCT level. At the end of the sixth month of the 
treatment, serum samples were collected for 
laboratory examination.  
This study was approved by the ethics 
committee of Ardabil University of Medical 
Sciences and informed consent was received 
from all patients. 
 
Procalcitonin test 
Samples were prepared according to the 
standards set. Firstly, labeled monoclonal 
antibodies were added to the additional samples 
and waited for reaction for 60 minutes at 37 °C. 
The samples were washed and chromogen 
solutions were added to them and were awaited 
for 10 min at 37°C for reactions. After 10 
minutes, the preventive solution was added to 
the sample. And then, the optical dentist (OD) 
level of samples were measured under light with 
a wavelength of 450 nm. The degree of PCT 
concentration in each sample was calculated 
based on the standard curve graph. All of these 
steps were done automatically by a machine 
(TKA ELISA) made in Italy. In this study, we used 
Human PCT ELISA Kit made in the U.S. 
 
Statistical Analysis 
After doing the experiments and completing 
the check lists, the data were inserted into SPSS 
statistical analysis software and then, it was 
analyzed using statistical methods including Chi-
Square and Paired Samples T–test. For evaluating 
the correlation between variables, Pearson 
correlation test was used. In all analyses, the P 
value lower than 0.05 was considered significant.  
 
Results 
Out of 42 patients, 55 percent were men and 
45 percent were women. The mean age of the 
patients was 45.48±12.54 and 30 cases, (71/4%), 
were between 35 to 65 years. Agriculture and 
farming were the most frequent job among the 
subjects. Two patients (4/8%) had previous TB 
disease. Eleven patients (26/2 %) had a positive 
family history for TB. Cough was the most 
common complaint among the patients in their 
[19 cases (45/2%)] (Table 1). 
The mean PCT levels before and after the 
treatment were 1.25±0.98 ng/ml and 0.4±0.11 
ng/ml, respectively (P<0.001). The mean ESR in 
the first hour before treatment was 45.8±21.9 
and after treatment was 14.38±10.25 (P<0.001). 
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Table 1. Patients’ demographic parameters  
Values  Parameters  
45.48±12.54  Age in years (mean ± SD)  
23/19 (55%/45%)  Male/Female  
25/17 (59%/41%)  Rural/Urban  
34/8(80%/20%)  Married/Unmarried  
9(21%)  History of Smoking(no.)  
11(26%) History of Familial TB(no.)  
19(45%)  Symptom of cough(no.) 
 
Table 3. The correlation between PCT and the research 
laboratory findings of the subjects 
PCT 
On admission 
P Value Correlation 
0.64– 0.07 ESR 
0.640.07 CRP 
0.10– 0.26 Neutrophil counts(ml) 
Correlation analyses were done by Pearson correlation test 
 
PCT 
After therapy 
P Value Correlation 
0.57– 0.01 ESR 
0.87– 0.03 CRP 
0.590.09 Neutrophil counts(ml) 
0.08– 0.28 Lymphocyte counts(ml) 
Correlation analyses were done by Pearson correlation test 
 
Analysis of the data showed that the amount of 
the ESR was significantly reduced with treatment 
(P<0.001) (Figure1 and 2). 
It was also observed that 52.4% of the patients 
before treatment had t ESR between 30-60, and 
after treatment 90 percent had their ESR below 30. 
The mean CRP was 7.16±3.98 mg/lit before 
the treatment and it was 3.13±1.34 mg/lit after 
the treatment. The difference was statistically 
significant (P<0.001). The results also showed 
that before treatment in 61.9% of patients, CRP 
was above 5 while after treatment in 95 percent 
of patients was below 5.  Number of the 
neutrophils before treatment were6221±3161 
cell/ml and after treatment 4411±2756. Also 
after the treatment the number of neutrophils 
reduced significantly (P=0.01). Lymphocytes 
were also counted and the results showed that 
they were 3528±1623 in number before 
treatment and 1557±530 after the treatment. 
After the treatment the number of the 
lymphocytes reduced and it was statistically 
significant (P<0.01) (Table 2). 
The results suggested that there was no 
significant correlation between PCT with age and 
gender (P=0.47 and P=0.96 respectively). There 
was no significant correlation between ESR and 
CRP before treatment with PCT level in patients 
(P=0.23 P=0.74 respectively); there was also no 
significant correlation between ESR and CRP 
after treatment with PCT level in patients (P=0.29 
P=0.86 respectively).  The serum PCT level in 
81% of the patients before the treatment was 
0.5ng/ml to 5ng/ml. At the end of the study after 
examining PCT level in patients before and after 
the treatment and analyzing the results with 
Table 2. Comparison of the results in patients before and 
after the treatment 
P ValueAfter terapyOnadmission Parameters 
P<0.0010.4±0.11 1.25±0.98 PCT in ng/ml(mean±SD) 
P<0.00114.38±10.25 45.8±21.9 ESR In mm/first hour (mean±SD) 
P<0.0013.13±1.34 7.16±3.98 CRP in mg/L(mean±SD) 
P<0.0018185±4594 12402±4445 WBC counts/ml(mean±SD) 
P<0.0011557±530 3225±1623 Lymphocyte counts/ml(mean±SD) 
P=0.01 4411±±27566221±3161 Neutrophil counts/ml(mean±SD) 
PCT: procalcitonin, ESR: erythrocyte sedimentation rate, CRP: 
C-reactive protein, WBC: white blood cell 
 
Figure 1 and 2. The mean serum level of ESR and PCT in 
patients before and after treatment 
 
Paired Sample Test, it was observed that after the 
treatment the level of PCT was reduced 
significantly (P<0.001). The relation between PCT 
and the research laboratory findings of the 
subjects before and after the treatment all are 
included in Table 3. 
 
Discussion 
The results of this study indicate that serum 
level of PCT in patients with active pulmonary 
tuberculosis has increased and this inflammatory 
marker can be used as a marker to distinguish 
active pulmonary tuberculosis from convalescent 
state, especially in countries with high prevalence 
of tuberculosis and in patients with clinical 
suspicion of TB. PCT can be used as a serum 
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inflammatory marker. 
 Although the high serum level of PCT is not a 
definite clue for diagnosing tuberculosis, it can be 
interpreted in favor of tuberculosis. Additionally, 
this inflammatory marker can be used in assessing 
the response to treatment. Before treatment, 81 
percent of patients had a PCT higher than 0.5 (cut 
of point in present study) which was reduced after 
treatment. Similar results have been found in 
some other studies (11-14).  
Although it is known as a marker of bacterial 
infection, the use of PCT in the diagnosis of 
infections is still controversial (15). Most studies 
on the use of PCT have been focused on 
distinguishing inflammation caused by the 
infection from non-infectious inflammatory 
factors (16). PCT level rises in bacterial infections 
(13) and low PCT indicates low risk of disease 
mortality (17). The maximum normal PCT level of 
serum is 0.5 ng/ml and for higher amounts the 
initiation of therapy is recommended (18). 
The production of PCT in patients with 
tuberculosis is not still known (10). Cellular 
defense mechanism in TB patients depends 
mainly on CD4+ T lymphocytes; these cells are 
multiplied and they produce numerous cytokines 
containing TNFα. Lipoarabinomanan is another 
molecule in the mycobacterium cell wall which is 
involved in the pathogen-host interaction and 
facilitates the survival of mycobacterium 
tuberculosis in macrophages (5, 19). In patients 
with TB, interleukin-1 (IL-1), IL-6, IL-10, TNFα, 
and other inflammatory cytokines increase and 
these cytokines can increase PCT independent 
from bacterial endotoxin and therefore they can 
explain the increase of PTC in cases other than 
bacterial infection (10, 20). Interferon γ (INF γ) is 
an important cytokine for inhibition of the 
mycobacterium and it can cause the production 
of PCT in patients with tuberculosis (14).  
In Baylan's study, PCT level has specifically 
increased in patients with tuberculosis. This 
study showed that PCT level is a specific but low-
sensitive marker in patients with pulmonary 
tuberculosis (10). In Schleicher et al. study 59% 
of patients with TB had high PCT; they have 
concluded that this marker has been helpful in 
patients with tuberculosis (20). 
Some have indicated that PCT in serum or 
pleural fluid may not be a useful parameter in the 
diagnosis of TB pleurisy. Although in patients 
with TB pleurisy the PCT level has increased 
more than non TB pleurisy, further studies are 
recommended (15). Malek Mohammad has 
shown that PCT is not a useful parameter for the 
diagnosis of TB pleurisy (12). In his study PCT 
amounts of pleural fluid have been investigated 
while in present study the serum level of PCT is 
examined. 
In this study the mean age was 45.48±12.54 
and the majority of cases (71%) were aged 
between 35 to 65 years. Age and sex patterns in 
present study are different from other studies (7, 
10,21) and the mean age was low (10,13). 
However there have been studies consistent with 
this study in which most patients were men (13) 
and the mean age was high (11,21). 
Since the majority of patients (59.5%) were 
from rural areas, the fact is that the population 
density in rural homes is higher and therefore the 
close contacts of family members are higher 
compared with urban population. 
The findings of the study show that 11 
patients had a family history of TB among their 
close relatives who have been diagnosed with 
active TB and this puts more emphasis on latent 
TB infection treatment or medications and must 
be considered in clinical guidelines for treatment 
of TB patients. 
In this study the mean ESR and CRP decreased 
significantly with treatment (P<0.001). The 
neutrophil count (P=0.01) and lymphocytes 
count (P<0.001) also decreased by treatment and 
this is in concordant with the results of other 
studies (7, 13). It can be concluded that although 
ESR and CPR are not diagnostic for TB, they are 
important clues in patients with TB and in 
patients with high ESR, CRP, and pulmonary 
symptoms, TB must be considered in differential 
diagnosis and additional diagnostic tests for 
sputum smear and sputum culture must be taken. 
The limitations of this study are the low 
sample size (because of lesser prevalence of 
pulmonary tuberculosis) and the lack of control 
group which can reduce the validity of study. A 
further study with a larger sample size and with 
control group is suggested. 
 
Conclusion 
This study shows that PCT level in patients 
with active pulmonary TB in the city of Ardabil 
has decreased after treatment. So it can be used 
for follow-up as a discriminative marker between 
active and cured pulmonary TB and predict 
treatment response and observing their recovery 
process although it cannot be an alternative for 
bacteriological and pathological diagnosis.  
 
Conflict of Interest 
Authors declare no conflict of interest. 
 
References 
1. Lange C, Sester M. TB or not TB: the role of 
immunediagnosis. Eur J Immunol. 2012; 42: 2840-3. 
2. Young DB, Gideon HP, Wilkinson RJ. Eliminating 
latent tuberculosis. Trends Microbiol. 2009; 17:183-
8. 
3. Delogu G, Zumbo A, Fadda G. Microbiological and 
immunological diagnosis of tuberculous 
 
 
Ghobadi H et al                    Serum Level of Procalcitonin in Patients with Active Pulmonary Tuberculosis                                 
 
242  J Cardiothorac Med. 2014; 2(4):238-242. 
 
 
spondylodiscitis. Eur Rev Med Pharmacol Sci. 2012; 
16:73-8. 
4. Baganha MF, Pego A, Lima MA, Gaspar EV, Cordeiro 
AR. Serum and pleural adenosine deaminase. 
Correlation with lymphocytic populations. Chest. 
1990; 97:605-10.  
5. Trajman A, Pai M, Dheda K, van Zyl Smit R, 
Zwerling A, Joshi R, et al. Novel tests for 
diagnosing tuberculous pleural effusion: what 
works and what does not? Eur Respir  J.  2008; 
31:1098-106. 
6. Maertzdorf J, Weiner J 3rd, Kaufmann SH. 
Enabling biomarkers for tuberculosis control. Int J 
Tuberc Lung Dis. 2012; 16:1140-8. 
7. Kang YA, Kwon S-Y, Yoon HI, Lee JH, Lee C-T. Role of 
C-Reactive Protein and Procalcitonin in 
Differentiation of Tuberculosis from Bacterial 
Community Acquired Pneumonia. Korean J Intern 
Med. 2009; 24:337-42. 
8. San Jose ME, Valdes L, Vizcaino LH, Mora T, Pose A, 
Soneira E, et al. Procalcitonin, C-reactive protein, and 
cell counts in the diagnosis of parapneumonic pleural 
effusions. J Investig Med. 2010; 58:971-6. 
9. Wang CY, Hsiao YC, Jerng JS, Ho CC, Lai CC, Yu CJ, 
et al. Diagnostic value of procalcitonin in pleural 
effusions. Eur J Clin Microbiol Infect Dis. 2011; 30: 
313-8. 
10. Baylan O, Balkan A, Inal A, Kisa O, Albay A, Doganci 
L, et al. The predictive value of serum procalcitonin 
levels in adult patients with active pulmonary 
tuberculosis. Jpn J Infect Dis. 2006; 59:164-7. 
11. Naderi M, Hashemi M, Kouhpayeh H, Ahmadi R. 
The status of serum procalcitonin in pulmonary 
tuberculosis and nontuberculosis pulmonary 
disease. J Pak Med Assoc. 2009; 59:647-8. 
12. Malekmohammad M, Naghan PA, Tabarsi P, 
Pourabdollah M, Mohajerani SA, Fotoohi F, et al. 
The diagnostic value of pleural effusion pro-
calcitonin level in different etiologies of exudative 
pleural effusion. Afr J Microbiol Res. 2012; 6:3237-
41. 
13. Rasmussen T, Sogaard O, Camara C, Andersen PL, 
Wejse C. Serum procalcitonin in pulmonary 
tuberculosis. Int J Tuberc Lung Dis. 2011; 15:251-
6. 
14. Ugajin M, Miwa S, Shirai M, Ohba H, Eifuku T, 
Nakamura H, et al. Usefulness of serum 
procalcitonin levels in pulmonary tuberculosis. 
Eur Respir J. 2010; 37:371-5. 
15. Cakir E, Deniz O, Ozcan O, Tozkoparan E, Yaman H, 
Akgul EO, et al. Pleural fluid and serum 
procalcitonin as diagnostic tools in tuberculous 
pleurisy. Clin Biochem. 2005; 38:234-8. 
16. Nyamande K, Lalloo U. Serum procalcitonin 
distinguishes CAP due to bacteria, Mycobacterium 
tuberculosis and PJP. Int J Tuberc Lung Dis. 2006; 
10:510-5. 
17. Kosanke R, Beier W, Lipecky R, Meisner M. Clinical 
Benefits of Procalcitonin. Tanaffos. 2008; 7:14-8. 
18. Christ-Crain M, Stolz D, Bingisser R, Müller C, 
Miedinger D, Huber PR, et al. Procalcitonin 
Guidance of Antibiotic Therapy in Community-
acquired Pneumonia: A Randomized Trial. Am J 
Respir Crit Care Med. 2006; 174:84-93.  
19. Roach DR, Bean AG, Demangel C, France MP, 
Briscoe H, Britton WJ. TNF regulates chemokine 
induction essential for cell recruitment, 
granuloma formation, and clearance of 
mycobacterial infection. J Immunol. 2002; 168: 
4620-7. 
20. Schleicher G, Herbert V, Brink A, Martin S, Maraj R, 
Galpin J, et al. Procalcitonin and C-reactive protein 
levels in HIV-positive subjects with tuberculosis 
and pneumonia. Eur  Respir J. 2005; 25:688-92. 
21. Hashemi A, Shojaei H, Heidarieh P, Aslani MM, 
Naser AD. Genetic diversity of Iranian clinical 
isolates of Mycobacterium tuberculosis. New 
Microbiol. 2012; 35:61-5. 
 
